Logo

PharmaShots Weekly Snapshots (November 01 - 03, 2021)

Share this
PharmaShots Weekly Snapshots (November 01 - 03, 2021)

PharmaShots Weekly Snapshots (November 01 - 03, 2021)

Lonza Collaborates with Codiak to Acquire its Exosomes Manufacturing Facility in Lexington, Massachusetts (US)

Published: Nov 3, 2021 | Tags: Lonza, Codiak, Acquire, Exosomes Manufacturing Facility, Lexington, Massachusetts, US

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

Published: Nov 3, 2021 | Tags: Amylyx, NDA, US, FDA, AMX0035, ALS

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

Published: Nov 3, 2021 | Tags: uniQure, P- I/II, Study, AMT-130, Huntington Disease

Ionis Initiates P-III CORE Study of Olezarsen for the Treatment of Severe Hypertriglyceridemia

Published: Nov 3, 2021 | Tags: Ionis, P-III, CORE Study, Olezarsen, Severe Hypertriglyceridemia

Roche Entered into a Clinical Trial Supply Agreement with Galecto to Evaluate GB1211 + Tecentriq (atezolizumab) in P-IIa Trial for 1L Treatment of NSCLC

Published: Nov 3, 2021 | Tags: Roche, Galecto, GB1211, Tecentriq, atezolizumab, P-IIa, Trial, NSCLC

Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies

Published: Nov 3, 2021 | Tags: Novartis, Dunad, Oral Targeted, Protein Degrader Therapies

Moderna Entered into a Research and Development Collaboration with Metagenomi to Develop In Vivo Gene Editing Therapeutics

Published: Nov 2, 2021 | Tags: Moderna, Metagenomi, In Vivo Gene Editing Therapeutics, Genetic Diseases

Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large B-Cell Lymphoma

Published: Nov 2, 2021 | Tags: Antengene, NMPA, IND, Approval, P-Ib, MATCH Study, ATG-008, onatasertib, ATG-010, Selinexor, Diffuse Large B-Cell Lymphoma

AstraZeneca Reports Results of Saphnelo in P-III TULIP Clinical Trial Program for the Treatment of Systemic Lupus Erythematosus

Published: Nov 2, 2021 | Tags: AstraZeneca, Saphnelo, P-III, TULIP Clinical Trial Program, Systemic Lupus Erythematosus

Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER-1 & 2 Trials for the Treatment of Active Psoriatic Arthritis

Published: Nov 2, 2021 | Tags: Janssen, Tremfya, guselkumab, P-III, DISCOVER-1, 2, Trials, Active Psoriatic Arthritis

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

Published: Nov 2, 2021 | Tags: Junshi, Coherus, US, FDA, BLA, Toripalimab, Nasopharyngeal Carcinoma

Merck Entered into a WW Research Collaboration and License Agreement with Synthekine to Develop Novel Cytokine Therapeutics

Published: Nov 2, 2021 | Tags: Merck, Synthekine, Cytokine Therapeutics, Autoimmune Diseases

Incyte Reports the US FDA's Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas

Published: Nov 1, 2021 | Tags: Incyte, US, FDA, NDA, Parsaclisib, R/R Non-Hodgkin Lymphomas

AstraZeneca to Divest Global Rights of Eklira and Duaklir to Covis Pharma in $270M Deal

Published: Nov 1, 2021 | Tags: AstraZeneca, Eklira, Duaklir, Covis Pharma, $270M

AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal Cell Carcinoma

Published: Nov 1, 2021 | Tags: AstraZeneca, Hutchmed, P-III, SAMETA Trial, Imfinzi, durvalumab, Savolitinib, Advanced Papillary Renal Cell Carcinoma

Novartis’ Scemblix (asciminib) Receives the US FDA's Approval for the Treatment of Chronic Myeloid Leukemia

Published: Nov 1, 2021 | Tags: Novartis, Scemblix, asciminib, US, FDA, Approval, Chronic Myeloid Leukemia

Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021

Published: Nov 1, 2021 | Tags: Merck, Keytruda, pembrolizumab, Studies, Melanoma, SMR 2021

Gilead Reports Interim Results of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in BICSTaR Study to Treat HIV

Published: Nov 1, 2021 | Tags: Gilead, Biktarvy, bictegravir, emtricitabine, tenofovir alafenamide, BICSTaR Study, HIV

Related Post: PharmaShots Weekly Snapshots (October 25 - 29, 2021)


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions